READI-CAT 2- barium sulfate suspension READI-CAT 2 BANANA SMOOTHIE- barium sulfate suspension READI-CAT 2 BERRY SMOOTHIE- barium sulfate suspension READI-CAT 2 MOCHACCINO SMOOTHIE- barium sulfate suspension READI-CAT 2 CREAMY VANILLA SMOOTHIE- barium sulfate suspension E-Z-EM Canada Inc		
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use READI-CAT 2 and READI-CAT 2 SMOOTHIE products safely and effectively. See full prescribing information for READI-CAT 2 (barium sulfate) oral suspension READI-CAT 2 SMOOTHIE (barium sulfate) oral suspension Initial U.S. Approval: 2016		
Warning and Precautions (5.6) 2/2017		
READI-CAT 2 and READI-CAT 2 SMOOTHIE are radiographic contrast agents, indicated for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients (1)  DOSAGE AND ADMINISTRATION  For oral use only:  Adults and pediatric patients 12 years and older: 450 mL to 900 mL (9 g to 18 g of barium sulfate, respectively) (2.1)  Patients younger than 12 years of age: scale down dose based on relative GI volume (2.1)		
DOSAGE FORMS AND STRENGTHS  Oral Suspension: 9 grams barium sulfate (2% w/v) supplied in a single dose HDPE plastic bottle (3)		
<ul> <li>Known or suspected perforation of the GI tract (4)</li> <li>Known obstruction of the GI tract (4)</li> <li>Conditions associated with high risk of GI perforation or aspiration (4)</li> <li>Known hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 products (4)</li> </ul>		
WARNINGS AND PRECAUTIONS		
<ul> <li>Hypersensitivity reactions: Emergency equipment and trained personnel should be immediately available (5.1)</li> <li>Intra-abdominal leakage: May occur in conditions such as GI fistula, ulcer, inflammatory bowel disease, appendicitis or diverticulitis, severe stenosis or obstructing lesions of the GI tract (5.2)</li> <li>Delayed GI transit and obstruction: Patients should maintain adequate hydration in days following a barium sulfate procedure to avoid obstruction or impaction (5.3)</li> <li>Aspiration: Caution is recommended in patients with history of food aspiration and in patients with known swallowing disorders (5.4)</li> </ul>		
ADVERSE REACTIONS		
Common adverse reactions include nausea, vomiting, diarrhea and abdominal cramping (6)  To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc at 1-800-257-5181 or FDA at 1-800-FDA-1088 or <a href="www.fda.gov/medwatch.">www.fda.gov/medwatch.</a> See 17 for PATIENT COUNSELING INFORMATION.		

**Revised: 2/2017** 

FULL PRESCRIBING INFORMATION: CONTENTS\* 100 INDICATIONS AND USAGE

#### 200DOSAGE AND ADMINISTRATION

- 2.1 Recommended Dosage
- 2.2 Administration Instructions

#### 3 DOSAGE FORMS AND STRENGTHS

#### **400CONTRAINDICATIONS**

#### **500WARNINGS AND PRECAUTIONS**

- 5.10 Hypersensitivity Reactions
- 5.2 Intra-abdominal Barium Leakage
- 5.3 Delayed Gastrointestinal Transit and Obstruction
- 5.4 Aspiration Pneumonitis
- 5.5 Systemic Embolization
- 5.6 Risk with Hereditary Fructose Intolerance

#### 600ADVERSE REACTIONS

#### **800USES IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

#### 1100DESCRIPTION

#### 1200CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.3 Pharmacokinetics

#### 1300NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### 16 II HOW SUPPLIED/STORAGE AND HANDLING

#### 17 II PATIENT COUNSELING INFORMATION

#### **FULL PRESCRIBING INFORMATION**

#### **100INDICATIONS AND USAGE**

READI-CAT 2 and READI-CAT 2 SMOOTHIES are indicated for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

#### 200DOSAGE AND ADMINISTRATION

#### 2.1 Recommended Dosage

Base dosing on individual needs and procedure to be performed.

- Adult and pediatric patients 12 years and older: 450 mL to 900 mL (9 g to 18 g of barium sulfate)
- Patients younger than 12 years of age: adjust dose based on relative GI volume

#### 2.2 Administration Instructions

- For oral use only
- Shake bottle vigorously for 30 seconds prior to oral administration
- Administer undiluted prior to scan
- Discard any unused suspension
- Advise patients to hydrate following the barium sulfate procedure

<sup>\*</sup> Sections or subsections omitted from the full prescribing information are not listed.

#### 3 DOSAGE FORMS AND STRENGTHS

Oral suspension: 9 grams of barium sulfate supplied as a suspension (2% w/v) in a single-dose HDPE plastic bottle.

#### 400CONTRAINDICATIONS

READI-CAT 2 products are contraindicated in patients:

- with known or suspected perforation of the GI tract
- with known obstruction of the GI tract
- at high risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis
- at high risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation
- known severe hypersensitivity to barium sulfate or any of the excipients of READI-CAT 2 or READI-CAT 2 SMOOTHIES

#### **500WARNINGS AND PRECAUTIONS**

#### 5.1 Hypersensitivity Reactions

Barium sulfate preparations contain a number of excipients, including natural and artificial flavors and may induce serious hypersensitivity reactions. The manifestations include hypotension, bronchospasm and other respiratory impairments, dermal reactions including rashes, urticaria, and itching. A history of bronchial asthma, atopy, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction.

#### 5.2 Intra-abdominal Barium Leakage

The use of READI-CAT 2 products is contraindicated in patients at high risk of perforation of the GI tract [see Contraindications (4)]. Administration of READI-CAT 2 products may result in leakage of barium from the GI tract in the presence of conditions such as carcinomas, GI fistula, inflammatory bowel disease, gastric or duodenal ulcer, appendicitis, or diverticulitis, and in patients with a severe stenosis at any level of the GI tract, especially if it is distal to the stomach. The barium leakage has been associated with peritonitis and granuloma formation.

#### 5.3 Delayed Gastrointestinal Transit and Obstruction

Orally administered barium sulfate may accumulate proximal to a constricting lesion of the colon, causing obstruction or impaction with development of baroliths (inspissated barium associated with feces) and may lead to abdominal pain, appendicitis, bowel obstruction, or rarely perforation. Patients with the following conditions are at higher risk for developing obstruction or baroliths: severe stenosis at any level of the GI tract, impaired GI motility, electrolyte imbalance, dehydration, on a low residue diet, taking medications that delay GI motility, and constipation, pediatric patients with cystic fibrosis or Hirschsprung disease, and the elderly [see Use in Specific Populations (8.4, 8.5)]. To reduce the risk of delayed GI transit and obstruction, patients should maintain adequate hydration following a barium sulfate procedure.

## 5.4 As piration Pneumonitis

The use of READI-CAT 2 products is contraindicated in patients at high risk of aspiration [see Contraindications (4)]. Oral administration of barium is associated with aspiration pneumonitis, especially in patients with a history of food aspiration or with compromised swallowing mechanism.

Vomiting following oral administration of barium sulfate may lead to aspiration pneumonitis. In patients at risk for aspiration, begin the procedure with a small ingested volume of READI-CAT 2 products. Discontinue administration of READI-CAT 2 products immediately if aspiration is suspected.

#### 5.5 Systemic Embolization

Barium sulfate products may occasionally intravasate into the venous drainage of the large bowel and enter the circulation as a "barium embolus" leading to potentially fatal complications which include systemic and pulmonary embolism, disseminated intravascular coagulation, septicemia and prolonged severe hypotension. Although this complication is exceedingly uncommon after oral administration of barium sulfate suspension, monitor patients for potential intravasation when administering barium sulfate.

#### 5.6 Risk with Hereditary Fructose Intolerance

READI-CAT 2 contains sorbitol which may cause severe reactions if ingested by patients with hereditary fructose intolerance, such as: vomiting, hypoglycemia, jaundice, hemorrhage, hepatomegaly, hyperuricemia, and kidney failure. Before administration of READI-CAT 2 assess patients for a history of hereditary fructose intolerance and avoid use in these patients.

#### **600ADVERSE REACTIONS**

The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:

- Nausea, vomiting, diarrhea and abdominal cramping
- Serious adverse reactions and fatalities include aspiration pneumonitis, barium sulfate impaction, intestinal perforation with consequent peritonitis and granuloma formation, vasovagal and syncopal episodes

#### **8** USES IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

Risk Summary

READI-CAT 2 products are not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug.

#### 8.2 Lactation

Risk Summary

READI-CAT 2 products are not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to READI-CAT 2.

#### 8.4 Pediatric Use

The efficacy of READI-CAT 2 in pediatric patients of all groups is based on successful opacification of the GI tract during radiographic procedures [see Clinical Pharmacology (12.1)].

READI-CAT 2 is contraindicated in pediatric patients with tracheo-esophageal fistula [see Contraindications (4)].

Pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see Warnings and Precautions (5.1)]. Pediatric patients with cystic fibrosis or Hirschsprung disease should be monitored for bowel obstruction after use [see Warnings and Precautions (5.3)].

#### 8.5 Geriatric Use

Clinical studies of READI-CAT 2 products do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

#### 1100DESCRIPTION

READI-CAT 2 and READI-CAT 2 SMOOTHIE (barium sulfate) are radiographic contrast agents supplied as a suspension (2% w/v) for oral administration. The active ingredient barium sulfate is designated chemically as BaSO<sub>4</sub> with a molecular weight of 233.4 g/mol, a density of 4.5 g/cm<sup>3</sup>, and the following chemical structure:

Ba<sup>2+</sup> 
$$\begin{bmatrix} 0 \\ 0 \\ 0 \end{bmatrix}^{2-}$$

READI-CAT 2 products contain excipients including: benzoic acid, citric acid, potassium sorbate, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol solution, xanthan gum, and purified water.

READI-CAT 2 products also contain natural and artificial flavorings including: banana, blueberry, orange, vanilla, chocolate, and coffee flavors.

#### 1200CLINICAL PHARMACOLOGY

#### 12.1 Mechanism of Action

Due to its high atomic number, barium (the active ingredient in READI-CAT 2 products) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.

#### 12.3 Pharmacokinetics

Under physiological conditions, barium sulfate passes through the GI tract in an unchanged form and is absorbed only in pharmacologically insignificant amounts.

#### 13 NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies have been performed to evaluate the carcinogenic potential of barium sulfate or potential effects on fertility.

#### 16 HOW SUPPLIED/STORAGE AND HANDLING

#### 16.1 How Supplied

READI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 %

w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.

READI-CAT 2 products are provided in the following flavors as:

READI-CAT 2: (Orange): 12 x 450 mL bottles (NDC 32909-744-03)

READI-CAT 2 SMOOTHIE (Banana): 12 x 450 mL bottles (NDC 32909-742-03)

READI-CAT 2 SMOOTHIE (Berry): 12 x 450 mL bottles (NDC 32909-741-03)

READI-CAT 2 SMOOTHIE (Creamy Vanilla): 12 x 450 mL bottles (NDC 32909-746-03)

READI-CAT 2 SMOOTHIE (Mochaccino): 12 x 450 mL bottles (NDC 32909-747-03)

#### 16.2 Storage and Handling

Store at USP controlled room temperature, 20 to 25°C (68 to 77° F)

#### 17 II PATIENT COUNSELING INFORMATION

After administration advise patients to:

- Maintain adequate hydration
- Seek medical attention for worsening of constipation or slow gastrointestinal passage
- Seek medical attention for any delayed onset of hypersensitivity: rash, urticaria, or respiratory difficulty.

Manufactured by EZEM Canada Inc Anjou (Quebec) Canada H1J 2Z4

For

Bracco Diagnostics Inc. Monroe Township, NJ 08831

Revised January 2020

CL10E801


Readi–Cat® 2 Barium Sulfate Suspension Labels

NDC: 32909-744-03

NDC 32909-744-03 12 x 450 mL **Bracco Diagnostics** BRACCO READI-CAT® 2 (BARIUM SULFATE) ORAL SUSPENSION (2% w/v) Single dose bottle - For oral use only For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients. Usual dosage: See prescribing information Each bottle contains 9 g barium sulfate and the following inactive ingredients: Citric acid, natural and artificial orange flavor, natural and artificial vanilla flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sorbitol, xanthan gum. Store at USP controlled room temperature, 20 to 25°C (68 to 77°F). Protect from freezing. LOT Rx only Lot and expiry encoding area 1"x 2" Manufactured for Bracco Diagnostics Inc. EXP Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada

rev. 01/20

CE10E501



Readi— $Cat^{\otimes}$  2 Barium Sulfate Suspension Labels — Banana Smoothie NDC: 32909-742-03

(01)30332909744039

12 x 450 mL NDC 32909-742-03 BANANA SMOOTHIE READI-CAT® 2 Single dose bottle - For oral use only Usual dosage: See prescribing information



#### (BARIUM SULFATE) ORAL SUSPENSION (2% w/v)

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

Each bottle contains 9 g barium sulfate and the following inactive ingredients:

Artificial vanilla flavor, benzoic acid, citric acid, natural banana flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum.

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F).

Protect from freezing.

Rx only

Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada

LOT

Lot and expiry encoding area

EXP

CE10E201



#### Single dose bottle - For oral use only

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

See prescribing information for complete dosage and administration information.

#### SHAKE WELL PRIOR TO USE

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F). Protect from freezing.

DO NOT USE IF INNER SEAL IS BROKEN OR MISSING



#### **Bracco Diagnostics**

rev. 01/20

450 mL NDC 32909-742-03

(BARIUM SULFATE) **ORAL SUSPENSION** 

For Oral Use Only Rx only

> Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada

(2% w/v)

Each bottle contains 9 g barium sulfate and the following inactive ingredients: Artificial vanilla flavor, benzoic acid, citric acid, natural banana flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum.

X, to

CI10E301


rev. 01/20

Readi-Cat® 2 Barium Sulfate Suspension Labels

NDC: 32909-741-03

12 x 450 mL NDC 32909-741-03 **Bracco Diagnostics BERRY SMOOTHIE** READI-CAT® 2 (BARIUM SULFATE) ORAL SUSPENSION (2% w/v) Single dose bottle - For oral use only For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients. Usual dosage: See prescribing information Each bottle contains 9 g barium sulfate and the following inactive ingredients: Benzoic acid, citric acid, natural and artificial blueberry flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum. Store at USP controlled room temperature, 20 to 25°C (68 to 77°F). Protect from freezing. LOT Rx only Lot/expiry encoding area Manufactured for Bracco Diagnostics Inc. EXP Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada CE10EC01

rev. 01/20



Readi–Cat<sup>®</sup> 2 Barium Sulfate Suspension Labels

(01)30332909741038

NDC: 32909-747-03

NDC 32909-747-03

12 x 450 mL

# MOCHACCINO SMOOTHIE READI-CAT® 2



#### (BARIUM SULFATE) ORAL SUSPENSION (2% w/v)

Single dose bottle - For oral use only

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients. Usual dosage: See prescribing information

Each bottle contains 9 g barium sulfate and the following inactive ingredients: Benzoic acid, citric acid, natural and artificial bavarian chocolate flavor, natural and artificial coffee cappuccino flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum.

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F).

Protect from freezing.

Rx only

Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada

(01)30332909747030

LOT

EXP

Lot and expiry encoding area

CE10E901



I10EAO'

# Single dose bottle – For oral use only

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

See prescribing information for complete dosage and administration information.

#### SHAKE WELL PRIOR TO USE

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F). Protect from freezing.

DO NOT USE IF INNER SEAL IS BROKEN OR MISSING COMPUTED TOMOGRAPHY STUDIES

Bracco Diagnostics

450 mL NDC 32909-747-03

rev. 01/20

MOCHACCINO SMOOTHIE READI-CAT® 2

(BARIUM SULFATE)
ORAL SUSPENSION

For Oral Use Only

(2% w/v)

Rx only

Manufactured for Bracco Diagnostics Inc.

Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada Each bottle contains 9 g barium sulfate and the following inactive ingredients: Benzoic acid, citric acid, natural and artificial bavarian chocolate flavor, natural and artificial coffee cappuccino flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum.

Lot Lot and expiry encoding area unvarrished

rev. 01/20

Readi–Cat<sup>®</sup> 2 Barium Sulfate Suspension Labels

NDC: 32909-746-03

NDC 32909-746-03

12 x 450 mL

# CREAMY VANILLA SMOOTHIE READI-CAT® 2



## (BARIUM SULFATE) ORAL SUSPENSION (2% w/v)

Single dose bottle - For oral use only

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

Usual dosage: See prescribing information

Each bottle contains 9 g barium sulfate and the following inactive ingredients: Artificial vanilla flavor, benzoic acid, citric acid, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol, xanthan gum.

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F).

Protect from freezing.

Rx only

Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada LOT

**EXP** 

Lot/expiry encoding area



(01)20222000746022

rev. 01/20

CE10EF01

Each bottle contains 9 g barium

sulfate and the following inactive ingredients: Artificial vanilla

flavor, benzoic acid, citric acid,

saccharin sodium, simethicone

emulsion, sodium benzoate,

sodium citrate, sorbitol,

xanthan gum.

potassium sorbate, purified water,



# Single dose bottle – For oral use only

For use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

See prescribing information for complete dosage and administration information.

#### SHAKE WELL PRIOR TO USE

Store at USP controlled room temperature, 20 to 25°C (68 to 77°F), Protect from freezing.

DO NOT USE IF INNER SEAL IS BROKEN OR MISSING COMPUTED TOMOGRAPHY STUDIES



#### BRACCO Bracco Diagnostics

450 mL NDC 32909-746-03

CREAMY VANILLA SMOOTHIE READI-CAT® 2

> (BARIUM SULFATE) ORAL SUSPENSION (2% w/v)

For Oral Use Only
Rx only

Manufactured for Bracco Diagnostics Inc. Monroe Twp., NJ 08831 by E-Z-EM Canada Inc, Anjou, Quebec H1J2Z4, Canada (01)10332909746039
Lot Lot and expiry encoding area unvarished

爨

CI10F001

rev. 01/20

#### **READI-CAT 2**

barium sulfate suspension

#### **Product Information**

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-724
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics				
Color	WHITE	Score		
Shape		Size		
Flavor	ORANGE	Imprint Code		
Contains				

F	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:32909-724- 03	24 in 1 CARTON	03/27/2017	
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Info	Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA208143	03/27/2017	05/31/2022	

# **READI-CAT 2 BANANA SMOOTHIE**

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-722	
Route of Administration	ORAL			

Active Ingredient/Active Moiety			
	Ingredient Name	Basis of Strength	Strength
	Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
benzoic acid (UNII: 8SKN0B0MIM)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
trisodium citrate dihydrate (UNII: B22547B95K)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics			
Color	WHITE	Score	
Shape		Size	
Flavor	BANANA, VANILLA	Imprint Code	
Contains			

Ш	Packaging			
	# Item Code	Package Description	Marketing Start Date	Marketing End Date
	NDC:32909-722- 03	24 in 1 CARTON	03/27/2017	04/30/2022
	1	450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	03/27/2017	04/30/2022

# **READI-CAT 2 BERRY SMOOTHIE**

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-711
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL	

Inactive Ingredients	
Ingredient Name	Strength
anhydrous citric acid (UNII: XF417D3PSL)	
benzoic acid (UNII: 8 SKN0 B0 MIM)	
dimethicone 350 (UNII: 2Y53S6ATLU)	
dimethicone 1000 (UNII: MCU2324216)	
potassium sorbate (UNII: 1VPU26JZZ4)	
silicon dioxide (UNII: ETJ7Z6XBU4)	
sodium benzoate (UNII: OJ245FE5EU)	
trisodium citrate dihydrate (UNII: B22547B95K)	
sorbitol (UNII: 506T60A25R)	
water (UNII: 059QF0KO0R)	
xanthan gum (UNII: TTV12P4NEE)	
saccharin sodium (UNII: SB8ZUX40TY)	

Product Characteristics			
Color	WHITE	Score	
Shape		Size	
Flavor	BLUEBERRY	Imprint Code	
Contains			

I	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:32909-711- 03	24 in 1 CARTON	03/27/2017	04/30/2022
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	03/27/2017	04/30/2022

## **READI-CAT 2 MOCHACCINO SMOOTHIE**

barium sulfate suspension

#### **Product Information**

Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:32909-777

Route of Administration ORAL

# Active Ingredient/Active Moiety

ı	, <b>g</b> ,		
	Ingredient Name	Basis of Strength	Strength
	Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

# **Inactive Ingredients**

Ingredient Name	Strength
anhydrous citric acid (UNII: XF417D3PSL)	
benzoic acid (UNII: 8 SKN0 B0 MIM)	
dimethicone 350 (UNII: 2Y53S6ATLU)	
dimethicone 1000 (UNII: MCU2324216)	
potassium sorbate (UNII: 1VPU26JZZ4)	
silicon dioxide (UNII: ETJ7Z6XBU4)	
sodium benzoate (UNII: OJ245FE5EU)	
trisodium citrate dihydrate (UNII: B22547B95K)	
sorbitol (UNII: 506T60A25R)	
water (UNII: 059QF0KO0R)	
xanthan gum (UNII: TTV12P4NEE)	
saccharin sodium (UNII: SB8ZUX40TY)	

## **Product Characteristics**

Color	WHITE	Score	
Shape		Size	
Flavor	COFFEE, CHOCOLATE	Imprint Code	

Contains

## **Packaging**

# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:32909-777-	24 in 1 CARTON	03/27/2017	03/31/2022
1	450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

# **Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	03/27/2017	03/31/2022

# **READI-CAT 2 CREAMY VANILLA SMOOTHIE**

barium sulfate suspension

## **Product Information**

Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:32909-756

Route of Administration ORAL

## **Active Ingredient/Active Moiety**

retive ingredient retive wrotety		
Ingredient Name	Basis of Strength	Strength
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
benzoic acid (UNII: 8SKN0B0MIM)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
trisodium citrate dihydrate (UNII: B22547B95K)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics				
Color	WHITE	Score		
Shape		Size		
Flavor	VANILLA	Imprint Code		
Contains				

F	ackaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:32909-756- 03	24 in 1 CARTON	03/27/2017	04/30/2022
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	03/27/2017	04/30/2022

## **READI-CAT 2**

<b>Product Information</b>			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-744
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL	

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics				
Color	WHITE	Score		
Shape		Size		
Flavor	ORANGE	Imprint Code		
Contains				

P	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:32909-744- 03	12 in 1 CARTON	11/01/2020	
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	11/01/2020	

## **READI-CAT 2 BANANA SMOOTHIE**

barium sulfate suspension

#### **Product Information**

Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:32909-742

Route of Administration ORAL

#### **Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
benzoic acid (UNII: 8 SKN0 B0 MIM)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
trisodium citrate dihydrate (UNII: B22547B95K)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics				
Color	WHITE	Score		
Shape		Size		
Flavor	BANANA, VANILLA	Imprint Code		
Contains				

ı	Packaging			
	# Item Code	Package Description	Marketing Start Date	Marketing End Date
	1 NDC:32909-742- 03	12 in 1 CARTON	11/01/2020	

# **Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	11/0 1/20 20	

## **READI-CAT 2 BERRY SMOOTHIE**

barium sulfate suspension

## **Product Information**

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-741
Route of Administration	ORAL		

# **Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients		
Ingredient Name	Strength	
anhydrous citric acid (UNII: XF417D3PSL)		
benzoic acid (UNII: 8 SKN0 B0 MIM)		
dimethicone 350 (UNII: 2Y53S6ATLU)		
dimethicone 1000 (UNII: MCU2324216)		
potassium sorbate (UNII: 1VPU26JZZ4)		
silicon dioxide (UNII: ETJ7Z6XBU4)		
sodium benzoate (UNII: OJ245FE5EU)		
trisodium citrate dihydrate (UNII: B22547B95K)		
sorbitol (UNII: 506T60A25R)		
water (UNII: 059QF0KO0R)		
xanthan gum (UNII: TTV12P4NEE)		
saccharin sodium (UNII: SB8ZUX40TY)		

Product Characteristics			
Color	WHITE	Score	
Shape		Size	
Flavor	BLUEBERRY	Imprint Code	
Contains			

Packaging			
# Itam Cada	Dackage Description	Marketing Start	Marketing End

#	Item Code	Package Description	Date	Date
1	NDC:32909-741- 03	12 in 1 CARTON	11/01/2020	
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA208143	11/0 1/20 20	

# **READI-CAT 2 MOCHACCINO SMOOTHIE**

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-747
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL

Inactive Ingredients			
Ingredient Name	Strength		
anhydrous citric acid (UNII: XF417D3PSL)			
benzoic acid (UNII: 8SKN0B0MIM)			
dimethicone 350 (UNII: 2Y53S6ATLU)			
dimethicone 1000 (UNII: MCU2324216)			
potassium sorbate (UNII: 1VPU26JZZ4)			
silicon dioxide (UNII: ETJ7Z6XBU4)			
sodium benzoate (UNII: OJ245FE5EU)			
trisodium citrate dihydrate (UNII: B22547B95K)			
sorbitol (UNII: 506T60A25R)			
water (UNII: 059QF0KO0R)			
xanthan gum (UNII: TTV12P4NEE)			
saccharin sodium (UNII: SB8ZUX40TY)			

Product Characteristics				
Color	WHITE	Score		
Shape		Size		
Flavor	COFFEE, CHOCOLATE	Imprint Code		
Contains				

P	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:32909-747- 03	12 in 1 CARTON	11/01/2020		
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product			

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA208143	11/0 1/20 20		

# READI-CAT 2 CREAMY VANILLA SMOOTHIE

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:32909-746
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
Barium Sulfate (UNII: 25BB7EKE2E) (Barium Sulfate - UNII:25BB7EKE2E)	Barium Sulfate	20 mg in 1 mL	

Inactive Ingredients			
Ingredient Name	Strength		
anhydrous citric acid (UNII: XF417D3PSL)			
benzoic acid (UNII: 8SKN0B0MIM)			
dimethicone 350 (UNII: 2Y53S6ATLU)			
dimethicone 1000 (UNII: MCU2324216)			
potassium sorbate (UNII: 1VPU26JZZ4)			
silicon dioxide (UNII: ETJ7Z6XBU4)			
sodium benzoate (UNII: OJ245FE5EU)			
trisodium citrate dihydrate (UNII: B22547B95K)			
sorbitol (UNII: 506T60A25R)			
water (UNII: 059QF0KO0R)			
xanthan gum (UNII: TTV12P4NEE)			
saccharin sodium (UNII: SB8ZUX40TY)			

Product Characteristics		
Color	WHITE	Score
Shape		Size
Flavor	VANILLA	Imprint Code

#### **Contains**

ŀ	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:32909-746- 03	12 in 1 CARTON	11/01/2020		
1		450 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product			

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA208143	11/0 1/20 20		

# Labeler - E-Z-EM Canada Inc (204211163)

# **Registrant -** BRACCO DIAGNOSTICS INC (849234661)

Estal	Establishment		
Name	Address	ID/FEI	Business Operations
E-Z-EM Canada Inc		204211163	ANALYSIS (32909-746, 32909-777, 32909-711, 32909-747, 32909-722, 32909-756, 32909-742, 32909-741, 32909-724, 32909-744), MANUFACTURE (32909-711, 32909-742, 32909-777, 32909-741, 32909-722, 32909-747, 32909-756, 32909-744, 32909-746, 32909-724)

Revised: 10/2020 E-Z-EM Canada Inc